Auris Medical AG announced that the Swiss-based company’s Phase III tinnitus trial for Keyzilen failed to meet endpoints.
Five months after the company’s lead drug began Phase I testing, San Diego-based Crinetics Pharmaceuticals Inc. secured $63.5 million in Series B financing.
FDA Accepts for Filing Supplemental Biologics License Application for Xeomin in Adult Patients with Sialorrhea
Merz North America announced today that the U.S. Food and Drug Administration accepted for filing a supplemental Biologics License Application for Xeomin (incobotulinumtoxinA) for the treatment of chronic sialorrhea (excessive drooling) due to Parkinson’s Disease or other neurologic disorders in adult patients.
The U.S. spends about twice what other high-income nations do on health care but has the lowest life expectancy and the highest infant mortality rates, a new study suggests.
Israeli drugmaker Teva rebuffed EU antitrust charges of making an illegal deal with rival Cephalon to delay selling a cheaper generic version of the latter’s sleep disorder drug at a hearing.
AbbVie and Neurocrine Biosciences announced that the Phase III ELARIS UF-II clinical trial of elagolix for uterine fibroids met its primary endpoint.
Tech companies, such as Google, Apple, Facebook, Amazon and others, have been making significant forays into the life sciences. Although many have praised the ambitions, innovation and deep pockets these companies bring to the industry, a new report by global consulting and advisory company EY suggests that life science companies are in danger of falling behind their tech brethren.
When popular retailers launch new products, they do not have to do much promotion to capture people’s interest. Consumers are so eager to nab their goods, they will buy out their inventories in days, and sometimes minutes. Healthcare “products,” on the other hand, rarely hold the same appeal.
The U.S. Food and Drug Administration granted Cambridge, Mass.-based Proteostasis Therapeutics‘ investigational cystic fibrosis add-on therapy Breakthrough Therapy Designation.
The U.S. FDA accepted Merck & Company’s supplemental Biologics License Application and granted Priority Review for Keytruda (pembrolizumab) in advanced cervical cancer.
W2O, an integrated network of complementary analytics-driven firms, reported another year of double-digit revenue growth with a 17.6 percent increase in revenue to $144.3 million in 2017.
UnitedHealth Group named its board member and former GlaxoSmithKline head Andrew Witty as chief executive of the health insurer’s pharmacy benefit unit Optum, effective July 1, 2018.
Shares of Advaxis Inc. were down more than 21 percent in after the company announced that the U.S. FDA halted a Phase I/II trial that uses an AstraZeneca Pharmaceuticals LP drug following the death of a patient.
Swiss drugmaker Roche expects to compensate or overcompensate for falling revenue from patent-expired drugs facing competition from rivals’ copies through its new medicines.
Gout sufferers with major pre-existing heart disease face a higher risk of death if they are treated with the drug febuxostat, a large long-term study has concluded.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
In the past few years, personal fitness trackers have become all the rage. It’s fun to see your daily activity level, sleep quality and heart rate. But, does knowing this data lead to any positive changes?
Realm Therapeutics Inc.’s PR013 failed to show efficacy in its Phase II trial for allergic conjunctivitis.
Impax Laboratories Inc. went to trial over claims by major retailers and consumers that the company agreed to delay launching a generic version of Solodyn in exchange for millions of dollars from the acne medication’s manufacturer.
Anthera Pharmaceuticals Inc. is evaluating all strategic options after the company’s lead drug failed in a late-stage trial, sending shares down 80 percent in premarket trading.